Nuevocor Therapeutics
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Cardiovascular
Nuevocor is a biotechnology company developing novel therapies for genetic cardiomyopathies driven by aberrant mechanobiology, headquartered in Singapore with offices in the U.S. and Europe. In 2025, Nuevocor closed a US$50 million financing from Kurma Partners, Angelini Ventures, EDBI, ClavystBio, Boehringer Ingelheim Venture Fund, Coronet Ventures and Highlight Capital. Our unique approach, enabled by our proprietary PrOSIA mechanobiology platform, surpasses the limitations of traditional gene replacement therapy – which treats individual gene mutations – to treating defects in shared disease pathways across multiple cardiomyopathies by addressing the functional root cause of disease. Nuevocor is first-in-disease by addressing genetic cardiomyopathies that are not amendable to gene replacement therapy and have no effective treatment options.
Company HQ City:
Fort Washington
Company HQ State:
PA
Company HQ Country:
United States
Year Founded:
2021
Lead Product in Development:
NVC-001, open IND and initiating first clinical trial in LMNA related dilated cardiomyopathy
CEO
Albert Gianchetti
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
1H2027
What is your next catalyst (value inflection) update?
Clinical trial results
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}